COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • July 17th, 2013 • Dyax Corp • Services-commercial physical & biological research • Texas
This Commercial Outsourcing Services Agreement (this “Agreement”) is entered into as of February 12, 2013 (the “Effective Date”) by Integrated Commercialization Solutions, Inc. (“ICS”) and Dyax Corp. (the “Company”).
COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • August 9th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • Texas
This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of April 14, 2011 (the “Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“ICS”) and Corcept Therapeutics, INC., a Delaware corporation (the “Company”).
FOURTH AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • November 6th, 2013 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
This Fourth Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between AMAG Pharmaceuticals, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of August 1, 2013 (the “Amendment Effective Date”).
COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • June 3rd, 2005 • Skinmedica Inc • Pharmaceutical preparations • California
This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of February 1, 2003 (“Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“Service Provider”) and SKINMEDICA, INC., a Delaware corporation (“Company”).
FIRST AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • August 5th, 2011 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
This First Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between AMAG Pharmaceuticals, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of April 14, 2011 (the “Amendment Effective Date”).
COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • February 10th, 2014 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of October , 2008 (the “Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“ICS”) and AMAG PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
THIRD AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • November 7th, 2012 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
This Third Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between AMAG Pharmaceuticals, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of August 1, 2012 (the “Amendment Effective Date”).
PORTIONS OF THIS EXHIBIT MARKED BY [**] HAVE BEEN OMITTED PURSUANT TO RULE 601(B)(10) OF REGULATION S-K. THE OMITTED INFORMATION IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. FOURTH AMENDMENT...Commercial Outsourcing Services Agreement • May 7th, 2020 • Pacira BioSciences, Inc. • Pharmaceutical preparations
This Fourth Amendment to the Commercial Outsourcing Services Agreement (this "Amendment") is between Pacira Pharmaceuticals, Inc. (the "Company") and Integrated Commercialization Solutions, Inc. ("ICS"). This Amendment is effective as of January 1, 2016 (the "Amendment Effective Date").
COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • July 1st, 2009 • Amag Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • Delaware
This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of October , 2008 (the “Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“ICS”) and AMAG PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
SECOND AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • August 8th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations
This Second Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between Corcept Therapeutics, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of June 11, 2014 (the “Amendment Effective Date”).
SECOND AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • December 22nd, 2011 • Amag Pharmaceuticals Inc. • Pharmaceutical preparations
This Second Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between AMAG Pharmaceuticals, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of December 1, 2011 (the “Amendment Effective Date”).
THIRD AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • November 7th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations
This Third Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between Corcept Therapeutics, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of August 11, 2014 (the “Amendment Effective Date”).
COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • February 29th, 2024 • Pacira BioSciences, Inc. • Pharmaceutical preparations • Delaware
This Commercial Outsourcing Services Agreement (this “Agreement”) is entered into as of February 26, 2024 (the “Effective Date”) by Integrated Commercialization Solutions, LLC (“ICS”) and Pacira Pharmaceuticals, Inc. (the “Company”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • October 31st, 2011 • Pacira Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of August 25, 2011 (the “Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“ICS”) and PACIRA PHARMACEUTICALS, INC., a California corporation (the “Company”).
COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • July 2nd, 2004 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of November 13, 2002 (“Effective Date”) by and between Integrated Commercialization Solutions, Inc., a California corporation (“Service Provider”) and Auxilium Pharmaceuticals, Inc., a Delaware corporation (“Company”).
FIRST AMENDMENT TO COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • August 8th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations
This First Amendment to the Commercial Outsourcing Services Agreement (this “Amendment”) is between Corcept Therapeutics, Inc. (the “Company”) and Integrated Commercialization Solutions, Inc. (“ICS”). This Amendment is effective as of April 14, 2014 (the “Amendment Effective Date”).
